General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TXVVI
ADC Name
XiRB49 MMAE
Synonyms
xiRB49 MMAE
   Click to Show/Hide
Organization
Université Paris-Saclay.; INRAE.; Inria.; Université de Bourgogne.; Université Paris Cité.; Université Sorbonne Paris Nord.
Drug Status
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
xiRB49
 Antibody Info 
Antigen Name
Endothelin-1 (EDN1)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mc-Val-Cit-PABC
 Linker Info 
Conjugate Type
Site-specific conjugation using new Q-tag substrate of bacterial transglutaminase
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.4&#1777.2
nM
CVCL_1779
Melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.4&#1777.2 nM Positive ET expression (ET+++/++)
Method Description
Cell cytotoxicity was monitored using a specific assay (Abcam, Cambridge, UK- Cat # 112118). This cytotoxicity assay is based on the measurement of mitochondrial dehydrogenase activity using a specific dye. This assay evaluates the metabolic activity of viable cells. Cells were plated at 1500 cells/well in 100 ul culture medium. The following day, 100 ul of increasing concentrations of mAb, diluted in culture medium, were added to each well. Cells were incubated for 96 h at 37 °C in a 5% CO2 incubator. The OD570/OD605 nm ratio was used to determine cell viability in each well in triplicate according to the instructions. Data were analyzed using Prism 9.4 (GraphPad Software San Diego, CA, USA) to determine the half maximal inhibitory concentration (IC50) using the variable slope model after checking that we had a normal distribution of these data by a D'Agostino & Pearson test.

   Click to Show/Hide
In Vitro Model Melanoma UACC-257 cells CVCL_1779
References
Ref 1 Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy